RP124/John C Martin Foundation[Grants and Funding] - Search Results

1

Editorial: Cardiometabolic criteria matters in MASLD-Authors' reply.

Tamaki N, Kimura T, Wakabayashi SI, Umemura T, Izumi N, Loomba R, Kurosaki M. Tamaki N, et al. Aliment Pharmacol Ther. 2024 Oct;60(8):1128-1129. doi: 10.1111/apt.18243. Epub 2024 Sep 3. Aliment Pharmacol Ther. 2024. PMID: 39224007 No abstract available.

2

Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.

Tamaki N, Kimura T, Wakabayashi SI, Umemura T, Kurosaki M, Loomba R, Izumi N. Tamaki N, et al. Aliment Pharmacol Ther. 2024 Jul;60(1):61-69. doi: 10.1111/apt.18015. Epub 2024 Apr 25. Aliment Pharmacol Ther. 2024. PMID: 38664876

3

Editorial: Has MetALD met the presumption? Authors' reply.

Tamaki N, Kimura T, Wakabayashi SI, Umemura T, Izumi N, Loomba R, Kurosaki M. Tamaki N, et al. Aliment Pharmacol Ther. 2024 Jul;60(1):99-100. doi: 10.1111/apt.18047. Epub 2024 May 17. Aliment Pharmacol Ther. 2024. PMID: 38757828 No abstract available.

4

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.

Noureddin N, Huang DQ, Bettencourt R, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Gidener T, Allen AM, Ajmera V, Loomba R. Noureddin N, et al. Aliment Pharmacol Ther. 2024 Jun;59(12):1521-1526. doi: 10.1111/apt.17981. Epub 2024 Apr 3. Aliment Pharmacol Ther. 2024. PMID: 38571305

5

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.

Bridi L, Agrawal S, Tesfai K, Madamba E, Bettencourt R, Richards LM, Khera AV, Loomba R, Ajmera V. Bridi L, et al. Aliment Pharmacol Ther. 2024 Aug;60(3):369-377. doi: 10.1111/apt.18099. Epub 2024 Jun 2. Aliment Pharmacol Ther. 2024. PMID: 38825972

6

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.

Lindén D, Tesz G, Loomba R. Lindén D, et al. Liver Int. 2024 Nov 28. doi: 10.1111/liv.16186. Online ahead of print. Liver Int. 2024. PMID: 39605307 Review.

7

Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver disease.

Tamaki N, Kimura T, Wakabayashi SI, Umemura T, Izumi N, Loomba R, Kurosaki M. Tamaki N, et al. Aliment Pharmacol Ther. 2024 Oct;60(8):1033-1041. doi: 10.1111/apt.18205. Epub 2024 Aug 8. Aliment Pharmacol Ther. 2024. PMID: 39115116

8

Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.

Kang MK, Song JE, Loomba R, Park SY, Tak WY, Kweon YO, Lee YR, Park JG. Kang MK, et al. Sci Rep. 2024 Oct 2;14(1):22917. doi: 10.1038/s41598-024-74287-7. Sci Rep. 2024. PMID: 39358447 Free PMC article.

9

Prevalence of Low FIB-4 in MASLD-Related Hepatocellular Carcinoma: A Multicentre Study.

Tan DJH, Tamaki N, Kim BK, Wijarnpreecha K, Aboona MB, Faulkner C, Kench C, Salimi S, Sabih AH, Lim WH, Danpanichkul P, Tay B, Teh Y, Mok J, Nah B, Ng CH, Muthiah M, Kulkarni AV, Lee SW, Liu K, Loomba R, Huang DQ; Global Liver Cancer Consortium. Tan DJH, et al. Aliment Pharmacol Ther. 2024 Oct 27. doi: 10.1111/apt.18346. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 39462858

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters